




# *Urethra-sparing SBRT for prostate cancer: dosimetric optimization with VMAT vs. IMRT and the learning curve effect*

Thomas Zilli, Zvi Symon, Samuel Bral, Anna Bruynzeel,  
Heikki Minn, Sandra Jorcano, Angelo Oliveira, Ufuk Abacioglu,  
Carmen Rubio, Raymond Miralbell

# Extreme hypofractionation: prostate SBRT



# SBRT principles

## STEREOTACTIC BODY RADIO THERAPY



**Hit precisely  
the target and  
spare OARs**

# SBRT principles

## STEREOTACTIC BODY RADIO THERAPY



Hit precisely  
the target and  
spare OARs

IGRT solutions

# SBRT principles


## STEREOTACTIC BODY RADIOtherapy



Hit precisely  
the target and  
spare OARs



IGRT solutions



Prostate  
SBRT

**SBRT for localized prostate cancer: the  
*Novalis Circle* prospective multicenter  
randomized phase II trial**



**NOVALISCIRCLE**

# Trial design



NOVALISCIRCLE

## Randomization

cT1c-T3a, GS ≤ 7,  
Roach index for N+ ≤ 20%;  
IPSS < 19; WHO 0-1

**7.25 Gy x 5 fx**  
(9 days, every other day)


**7.25 Gy x 5 fx**  
(28 days, once a week)

[Clinicaltrial.gov NCT01764646](https://clinicaltrials.gov/ct2/show/study/NCT01764646)


# *The Novalis Circle Trial*



NOVALISCIRCLE



# Cumulative Accrual



# Treatment schedule: urethra sparing

## PTV = Prostate ± SV (excluding urethral PRV)

# fractions	dose/fraction (Gy)	Total dose (Gy)	$\alpha/\beta$ (Gy)	NTD2Gy
5	7.25	36.25	1.5	90
5	7.25	36.25	3.0	74
5	7.25	36.25	10.0	50 (9d OTT) 39 (28d OTT)

TUMOR  
LATE TOX  
ACUTE TOX


## Urethral\_PRV

# fractions	dose/fraction (Gy)	Total dose (Gy)	$\alpha/\beta$ (Gy)	NTD2G
5	6.5	32.5	1.5	74
5	6.5	32.5	3.0	62


TUMOR  
LATE TOX

# 1. Treatment volumes: urethra sparing

- Prostate PTV (5 mm except posteriorly, 3 mm)
- Urethral PRV (planning risk volume)




PLANNING MRI



- 3 mm isotropic margins around the catheter / MRI urethra
- Includes both "urethras"

## 2. IGRT: fiducials + ERB



+




# 3. Technology: Novalis







- 6-axis-couch
  - Real 3D-repositioning
  - Submillimeter accuracy
  - Dynamic approach: respiration compensation

ExacTrac® system



# 4. Urethra-sparing: IMRT - VMAT



# Aims of the study

## Aims:

- 1. To compare the dosimetric results of intensity-modulated radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT)**
- 2. To assess the learning curve effect on dosimetric optimization with VMAT**

# 1. Materials and Methods

## Dosimetric optimization IMRT vs VMAT

- *Dosimetric data* of the first **40 patients** randomized between 07/2012 and 03/2014 in 9 different centers
- 20 patients treated on **prostate only**
- 20 patients treated on **prostate + seminal vesicles**
- Plans generated using either a **VMAT** (n=20) or **IMRT** (n=20) technique, with each modality including (n=10) or not (n=10) seminal vesicles in the PTV
- *Parameters*: mean doses ( $\pm$  SD) to the PTV, uPRV, OARs, PTV homogeneity index (HI) and dice similarity coefficient (DSC)

## 2. Materials and Methods

### Learning curve effect in VMAT optimization

- *Multicenter analysis*: VMAT plans of the first 20 patients were compared with VMAT plans generated in the last 20 randomized patients (05/2014-08/2015)
- *Institutional analysis* : 25 VMAT plans (Geneva, 2012-2015)

# 1. Dosimetric results: IMRT vs VMAT

		<i>Constraints ICRU 83</i>	<i>IMRT</i>	<i>VMAT</i>	<i>p-value</i>
Monitor Units			3685	2245	<i>p</i> =.0001
Homogeneity index			0.11	0.09	<i>p</i> =.002
Urethral PRV	$D_{98\%}$	$\geq 30.9$ Gy	30.1 Gy	31.2 Gy	<i>p</i> =.001
Rectal wall	$v_{100\%}$	< 5%	1.6±1.4%	2.5±1.9%	<i>p</i> =NS
	$v_{90\%}$	< 10-15%	10.3±3.0%	11.0±3.3%	<i>p</i> =NS
	$v_{80\%}$	< 20-25%	16.2±3.7%	14.8±4.2	<i>p</i> =NS
Bladder wall	$v_{100\%}$	< 10-15%	7.8±3.7%	7.0±3.8%	<i>p</i> =NS
	$v_{90\%}$	< 20%	15.3±4.0%	13.1±4.8%	<i>p</i> =NS
	$v_{50\%}$	< 40-50%	37.2±9.2%	28.4±11.6%	<i>p</i> =.011


## 2. Learning curve effect in VMAT

Last 20 VMAT plans vs. first 20 VMAT plans  
(*multicenter analysis*)


- PTV DSC value = 0.88 vs. 0.78,  $p=.009$
- Rectal wall  $V_{100} = 1.3\%$  vs.  $2.5\%$ ,  $p=.023$
- Bladder wall  $V_{100}$ ,  $V_{90}$  and  $V_{80} =$  overall significant better sparing in last VMAT plans,  $p<.05$

# 2. Learning curve effect in VMAT

*Institutional analysis* : 25 VMAT plans  
(Geneva University Hospital, 2012-2015)




#patients




#patients





# 2. Learning curve effect in VMAT



Optimization on rectal wall




# 2. Learning curve effect in VMAT



# Conclusions

- For all participating centers, urethra-sparing SBRT plans met all the dosimetric endpoints in terms of PTV coverage as well as OAR sparing, irrespectively of the technique used.
- Compared with IMRT, VMAT plans resulted in more homogeneous dose distribution, reduced number of MU, and better uPRV coverage.
- Conformality and OAR sparing with VMAT may be improved after gaining experience in SBRT plan optimization.

# Thank you for your attention!



*Ceci n'est pas une prostate*